sFgl2 gene-modified MSCs may promote the differentiation of Treg cells by enhancing the phosphorylation of SHP2 and SMAD2/3, inhibit the differentiation of Th17 and Th1 cells, and have a significant immune regulation effect (Fig. 8), so as to better treat experimental AIH mice, and it provides a possible strategy for the clinical treatment of AIH. The gene discussed is PTPN11; the disease is autoimmune hepatitis.